Table 5. Association of loci on chromosomes 2q34 and 5q14.1 with risk of CAD in the GeneBank Cohort.
| SNP (locus) | OR (95% CI) |
||||
|---|---|---|---|---|---|
| rs715 (2q34) | n | TT | TC | CC | P-value |
| CAD−/CAD+ | 1,966/6,507 | 1 | 0.97 (0.86–1.09) | 0.83 (0.69–1.01) | 0.10 |
| No CAD/mild CAD | 2,324/3,257 | 1 | 0.97 (0.86–1.10) | 0.84 (0.69–1.02) | 0.12 |
| No CAD/severe CAD | 2,324/2,892 | 1 | 0.94 (0.83–1.07) | 0.68 (0.55–0.85) | 2.6 × 10−3 |
| rs16876394 (5q14.1) | n | TT | TC | CC | P-value |
| CAD−/CAD+ | 1,853/6,131 | 1 | 0.98 (0.84–1.13) | 0.72 (0.40–1.30) | 0.46 |
| No CAD/mild CAD | 2,195/3,090 | 1 | 1.08 (0.93–1.25) | 0.89 (0.48–1.66) | 0.44 |
| No CAD/severe CAD | 2,195/2,699 | 1 | 0.99 (0.84–1.16) | 0.85 (0.43–1.65) | 0.74 |
| rs557302 (5q14.1) | n | GG | GA | AA | P-value |
| CAD−/CAD+ | 1,983/6,568 | 1 | 1.06 (0.93–1.21) | 1.00 (0.85–1.17) | 0.97 |
| No CAD/mild CAD | 2,346/3,291 | 1 | 1.04 (0.91–1.19) | 1.01 (0.86–1.18) | 0.90 |
| No CAD/severe CAD | 2,346/2,914 | 1 | 1.11 (0.96–1.28) | 1.04 (0.88–1.24) | 0.60 |
| rs617219 (5q14.1) | n | AA | AC | CC | P-value |
| CAD−/CAD+ | 1,992/6,510 | 1 | 1.06 (0.94–1.20) | 1.05 (0.88–1.26) | 0.41 |
| No CAD/mild CAD | 2,345/3,260 | 1 | 1.04 (0.92–1.17) | 1.11 (0.92–1.32) | 0.27 |
| No CAD/severe CAD | 2,345/2,897 | 1 | 1.10 (0.96–1.25) | 1.11 (0.91–1.35) | 0.17 |
CAD, coronary artery disease; CI, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism.
CAD severity was defined as having≥50% stenosis in 1 or 2 (mild) or≥3 (severe) major epicardial arteries at the time of cardiac evaluation. OR with 95% CI were obtained from logistic or multinomial regression adjusted for age, sex, medication use (statins or aspirin) and Framingham ATP-III risk score. Significant associations at a Bonferroni-corrected threshold of P<4.2x10−3 (0.05/4 SNPs × 3 phenotypes) are highlighted in bold.